Lenalidomide Teva

Lenalidomide, the active ingredient in Lenalidomide Teva, is an Immunomodulatory agent presented as a tablet (strength not specified) for oral use. It is used to treat certain blood cancers, including multiple myeloma and myelodysplastic syndromes, in adult patients.

GNH USA supplies Lenalidomide Teva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Lenalidomide is employed in the management of hematologic malignancies and related disorders.

Multiple Myeloma: improves progression‑free survival and overall response rates. Myelodysplastic Syndromes: reduces transfusion dependence and delays disease progression. Relapsed or Refractory Multiple Myeloma: provides therapeutic benefit as a maintenance or salvage option.

Lenalidomide may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Fatigue or weakness - Neutropenia (low neutrophil count) - Thrombocytopenia (low platelet count) - Diarrhea or constipation - Nausea and vomiting - Rash or pruritus

Serious or Rare Side Effects: - Venous thromboembolism (deep vein thrombosis, pulmonary embolism) - Severe infections (pneumonia, sepsis) - Secondary primary malignancies - Hepatic dysfunction or failure - Severe cutaneous reactions (Stevens‑Johnson syndrome)

Before initiating therapy, clinicians should assess baseline parameters and monitor patients regularly.

Monitor Blood Counts: perform complete blood count weekly during the first cycles. Assess Thrombotic Risk: evaluate history of clotting disorders and consider prophylactic anticoagulation. Evaluate Renal Function: adjust dosing in patients with impaired clearance. Contraception Counseling: advise both male and female patients of teratogenic risk and use effective contraception. Avoid Live Vaccines: do not administer live attenuated vaccines during treatment. Store at below 25°C: keep in the original container, protect from moisture and direct sunlight.

Lenalidomide can interact with other medicines, affecting efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine) – may reduce drug exposure. - Anticoagulants (e.g., warfarin) – increased risk of bleeding. - Live vaccines – heightened risk of infection.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., ketoconazole) – may modestly increase exposure. - NSAIDs – may exacerbate thrombocytopenia. - Digoxin – monitor serum levels as lenalidomide may affect renal clearance.